• Aucun résultat trouvé

Note-taking template for Country COVID-19 Intra-Action Review (IAR) Pillar 10: COVID-19 Vaccination[COUNTRY]Date(s) of Intra-Action Review: [DD/MM/YYYY]

N/A
N/A
Info
Télécharger
Protected

Academic year: 2022

Partager "Note-taking template for Country COVID-19 Intra-Action Review (IAR) Pillar 10: COVID-19 Vaccination[COUNTRY]Date(s) of Intra-Action Review: [DD/MM/YYYY]"

Copied!
12
0
0

Chargement.... (Voir le texte intégral maintenant)

Texte intégral

(1)

Country COVID-19 intra-action review (IAR) Note-taking template: Pillar 10, COVID-19 vaccination

28 April 2021

Note-taking template for Country COVID-19 Intra-Action Review (IAR) Pillar 10: COVID-19 Vaccination

[COUNTRY]

Date(s) of Intra-Action Review: [DD/MM/YYYY]

Instructions:

This template will be used by the notetaker during the IAR.

In the table, the sections on “Best practices” and on “Challenges” should be completed during the session “STEP 1”. The section on

“Prioritized actions” should be completed during the session “STEP 2”.

PILLAR 10 : COVID-19 Vaccination Document Existing Systems

Note if new programme or adaptations to existing systems were required 1. Programmes for vaccination of

COVID-19 risk groups

2. National Immunization Technical Advisory Group (NITAG)

3.

Adverse events following immunization (AEFI) causality assessment committee

PILLAR 10 : COVID-19 Vaccination Section A: Regulatory Preparedness

(2)

1. Best practice 1: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

2. Best practice 2: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

3. Best practice 3: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

… …

CHALLENGES IMPACT(S) LIMITING FACTORS

1. Challenge 1: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

2. Challenge 2: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

3. Challenge 3: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

… …

PILLAR 10 : COVID-19 Vaccination Section B: Planning, Coordination, & Service Delivery

(3)

1. Best practice 1: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

2. Best practice 2: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

3. Best practice 3: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

… …

CHALLENGES IMPACT(S) LIMITING FACTORS

1. Challenge 1: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

2. Challenge 2: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

3. Challenge 3: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

… …

PILLAR 10 : COVID-19 Vaccination Section C: Funding

(4)

1. Best practice 1: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

2. Best practice 2: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

3. Best practice 3: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

… …

CHALLENGES IMPACT(S) LIMITING FACTORS

1. Challenge 1: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

2. Challenge 2: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

3. Challenge 3: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

… …

PILLAR 10 : COVID-19 Vaccination Section D: Supply Chain & Waste Management

(5)

1. Best practice 1: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

2. Best practice 2: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

3. Best practice 3: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

… …

CHALLENGES IMPACT(S) LIMITING FACTORS

1. Challenge 1: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

2. Challenge 2: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

3. Challenge 3: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

… …

PILLAR 10 : COVID-19 Vaccination Section E: Human Resource Management & Training

(6)

1. Best practice 1: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

2. Best practice 2: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

3. Best practice 3: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

… …

CHALLENGES IMPACT(S) LIMITING FACTORS

1. Challenge 1: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

2. Challenge 2: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

3. Challenge 3: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

… …

PILLAR 10 : COVID-19 Vaccination Section F: Vaccine Acceptance & Demand

(7)

1. Best practice 1: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

2. Best practice 2: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

3. Best practice 3: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

… …

CHALLENGES IMPACT(S) LIMITING FACTORS

1. Challenge 1: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

2. Challenge 2: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

3. Challenge 3: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

… …

PILLAR 10 : COVID-19 Vaccination Section G: Vaccine Safety

(8)

1. Best practice 1: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

2. Best practice 2: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

3. Best practice 3: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

… …

CHALLENGES IMPACT(S) LIMITING FACTORS

1. Challenge 1: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

2. Challenge 2: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

3. Challenge 3: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

… …

PILLAR 10 : COVID-19 Vaccination Section H: Monitoring & Evaluation

(9)

1. Best practice 1: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

2. Best practice 2: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

3. Best practice 3: Impact 1:

Impact 2:

Enabling factor 1:

Enabling factor 2:

Enabling factor 3:

… …

CHALLENGES IMPACT(S) LIMITING FACTORS

1. Challenge 1: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

2. Challenge 2: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

3. Challenge 3: Impact 1:

Impact 2:

Limiting factor 1:

Limiting factor 2:

Limiting factor 3:

… …

PILLAR 10 : COVID-19 Vaccination Improve the ongoing COVID-19 vaccine roll-out 1.

(10)

would do differently or change about the COVID-19 vaccination programme going forward?

2.

What best practices can be identified from the country’s implementation of COVID-19 immunization, and how can these be further strengthened and instituted?

3.

What is the most important piece of advice you would give another country just starting their program?

PRIORITIZED ACTIONS

TIMELINE &

DESIRED DATE FOR COMPLETION

RESPONSIBLE FOCAL POINT

ESTIMATED BUDGET AND

FINANCIAL SOURCE

REQUIRED

SUPPORT INDICATORS

A. For immediate implementation:

1.

2.

3.

… …

(11)

1.

2.

3.

…

© World Health Organization 2021. Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.

WHO reference number : WHO/2019-nCoV/Country_IAR/templates/note_taking/vaccination/2021.1

Références

Télécharger maintenant ( DOCX - 12 Page - 307.11 KB )

Documents relatifs

MALADIES NEUROMUSCULAIRES ET VACCINATION COVID-19

Comme tous les vaccins, ils peuvent donner des effets secondaires bénins et de courte durée : fatigue, maux de tête, fièvre, frissons, … Ces effets sont plus

Vaccination contre la Covid-19

• Dans l’attente de cet avis, le vaccin AZ est indiqué pour les patients de plus de 18 ans y compris avec facteurs de comorbidité à l’exception d’allergie sévère à un

Vaccination COVID-19 et soignants

Ainsi, la Société de Pathologie Infectieuse de Langue Française et son groupe Vaccination Prévention appellent toutes les personnes travaillant dans le domaine de la santé, quel

Vaccination COVID-19

La Société de Pathologie Infectieuse de Langue Française (SPILF) affirme sa confiance dans l'évaluation que les organismes ayant pour rôle et mission d’évaluer les produits de

actualisation vaccination covid-19

o Comparaison du risque d’infection chez les contacts sous le même toit non vaccinés de cas index PCR+ vaccinés versus non vaccinés.. o Ajustement sur semaine calendaire,

ISO Plan d Action COVID-19

Toute personne ayant été en contact étroit avec un cas confirmé de COVID-19 doit surveiller les symptômes et en informer le directeur et l'infirmière scolaire avant de retourner

Country COVID-19 intra-actionreview (IAR):Participant feedback form23 July 2020

The IAR contributed to strengthening interdisciplinary collaboration and coordination among the health sector stakeholders involved in the COVID-19 outbreak

Rapid review of COVID-19

Dr Allan is a family physician, Director of Programs and Practice Support at the College of Family Physicians of Canada, and Professor in the Department of Family Medicine at